Shaik Fakiruddin et al., 2018 - Google Patents
Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumourShaik Fakiruddin et al., 2018
View HTML- Document ID
- 16662605805334101506
- Author
- Shaik Fakiruddin K
- Ghazalli N
- Lim M
- Zakaria Z
- Abdullah S
- Publication year
- Publication venue
- International journal of molecular sciences
External Links
Snippet
Tapping into the ability of engineered mesenchymal stem cells (MSCs) to mobilise into the tumour has expanded the scope of cancer treatment. Engineered MSCs expressing tumour necrosis factor (TNF)-related apoptosis inducing ligand (MSC-TRAIL) could serve as a …
- 210000002901 Mesenchymal Stem Cells 0 title abstract description 169
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shaik Fakiruddin et al. | Mesenchymal stem cell expressing TRAIL as targeted therapy against sensitised tumour | |
| Mizuno et al. | Prostaglandin E2/EP signaling in the tumor microenvironment of colorectal cancer | |
| Vaish et al. | Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting | |
| Dominiak et al. | Communication in the cancer microenvironment as a target for therapeutic interventions | |
| Weinberg et al. | Reactive oxygen species in the tumor microenvironment: an overview | |
| Barbato et al. | Cancer stem cells and targeting strategies | |
| Poltavets et al. | Macrophage modification strategies for efficient cell therapy | |
| Rhee et al. | Mesenchymal stem cell-mediated effects of tumor support or suppression | |
| Krishnamoorthy et al. | Immunosuppressive effects of myeloid-derived suppressor cells in cancer and immunotherapy | |
| Fernández-Francos et al. | Mesenchymal stem cell-based therapy as an alternative to the treatment of acute respiratory distress syndrome: current evidence and future perspectives | |
| Zhang et al. | Mechanisms of immunosuppression in colorectal cancer | |
| Cheever et al. | Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors | |
| Wang et al. | Targeting myeloid-derived suppressor cells in cancer immunotherapy | |
| Santos et al. | Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers | |
| Zhong et al. | Low dose cyclophosphamide modulates tumor microenvironment by TGF-β signaling pathway | |
| Shaik Fakiruddin et al. | Targeting of CD133+ cancer stem cells by mesenchymal stem cell expressing TRAIL reveals a prospective role of apoptotic gene regulation in non-small cell lung cancer | |
| Tripodi et al. | Oncolytic adenoviruses for cancer therapy | |
| Choi et al. | The janus face of IL-33 signaling in tumor development and immune escape | |
| Annan et al. | Tumor endothelial cell—a biological tool for translational cancer research | |
| Jo et al. | Innovative CAR-T cell therapy for solid tumor; current duel between CAR-T spear and tumor shield | |
| Dao et al. | TIM-3 expression is downregulated on human NK cells in response to cancer targets in synergy with activation | |
| Hattori et al. | Natural killer immunotherapy for minimal residual disease eradication following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia | |
| Mohr et al. | MSC. sTRAIL has better efficacy than MSC. FL-TRAIL and in combination with AKTi blocks pro-metastatic cytokine production in prostate cancer cells | |
| Yang et al. | 5-Fluorouracil suppresses colon tumor through activating the p53-fas pathway to sensitize myeloid-derived suppressor cells to FasL+ cytotoxic t lymphocyte cytotoxicity | |
| Vu et al. | Cancer resistance to immunotherapy: molecular mechanisms and tackling strategies |